| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: ARYX |
| Security Type |
Common Stock |
| Lead Underwriter |
Morgan Stanley |
| Days In Registration |
70 |
| Date Filed |
30-Aug-2007 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2009) |
| Industry |
Manufacturing |
| Business Description |
ARYx Therapeutics Inc, located in Fremont, California, manufactures prescription pharmaceuticals intended for final consumption, including biotech products and antibiotics. |
| Revenue |
$4.2M |
| Net Income |
-$27.6M |
| Shares Outstanding (post-offering) |
17.54M |
| Contact |
- |
| Number of Employees |
70 |
|
| Original Filing Information |
| US |
| Shares Filed |
5.0M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
5.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
750.0K |
| File Amount |
$75.0M |
| File Price Range |
$16.00 - $14.00 |
| File Mid Price |
$15.00 |
Current Filing Information
(Amended 5-Nov-2007) |
|
US |
|
Shares Filed |
5.0M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
5.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$75.0M |
| · % Change from Original |
0.0 |
| File Price Range |
$16.00 - $14.00 |
| File Mid Price |
$15.00 |
|
